

KLAUBER & JACKSON

ATTORNEYS AT LAW CONTINENTAL PLAZA 411 HACKENSACK AVENUE HACKENSACK, NEW JERSEY 07601

PATENT, TRADEMARK AND COPYRIGHT CAUSES (201) 487-5800

FACSIMILE: (201) 343-1684

INTERNET: 626-1210@MCIMAIL.COM/ 2-3-76

COUNSEL JACK MATALON LAWRENCE D. MANDEL

*BAR OTHER THAN N.J.

November 12, 1996

RECEIVED NOV 2 6 1996 GROUP 1000

Assistant Commissioner of Patents Washington, D.C. 20231

Attention:

Examiner P. Twomey

Group Art Unit 1804

Re: U.S. Patent Application

Applicant(s): Jeffrey Friedman et al.

Title:

MODULATORS OF BODY WEIGHT,

CORRESPONDING NUCLEIC ACIDS AND

PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC

USES THEREOF

Serial No.:

08/485,943

Filed:

June 7, 1995

Docket No.: 600-1-087 CIP2I

· CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER OF PATENTS, WASHINGTON, DC 20231 on November 12, 1996.

Paul F. Fehlner, Reg. No. 35,135 (Name of Registered Representative)

(Signature and Date)

SUBMISSION OF SEQUENCE LISTING

Sir:

Responsive to the Notice dated October 10, 1996 (copy enclosed), and in accordance with 37 CFR 1.821-1.825, Applicants submit herewith the following:

1. A paper copy of a Sequence Listing for insertion into the Application as filed at the end of the Specification and prior to the Claims.

Assistant Commissioner of Patents November 12, 1996 Page 2

2. A copy of the Sequence Listing in computer readable form (ASCII text), submitted on a 3½" floppy disk compatible with IBM format.

Docket No.: 600-1-087 CIP2I

- 3. A statement in support of the filing and submission of a Sequence Listing in accordance with 37 CFR 1.821 1.825.
- 4. A copy of the Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

The time set for this response is November 12, 1996, as November 10 fell on a Sunday and November 11 fell on a federal holiday.

Applicants request favorable consideration and entry of the Sequence Listing submitted herewith and further and favorable processing of the present Application.

Applicants hereby authorize that any charges in addition to the above authorized that relate to the filing and processing of the present Application in accordance with 37 CFR 1.16 and 1.17 may be charged to Deposit Account No. 11-1153. A duplicate copy of this letter is provided for this purpose.


Respectfully submitted,

Paul F. Fehlner, Ph.D. Attorney for Applicant(s)

Registration No. 35,135

PFF/rf Enclosures







UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

FIRST NAMED APPLICANT

ATTORNEY DOCKET NO.

08/485,943

6/7/95

Friedman, J.M.

FWOMEY - 600-1-087-CI

18N2/1010 -

DAVID A JACKSON ELAURER & JACKSON 411 HACKENBACK AV

411 HACKENBACK AVENUE DECENTED HACKENBACK NJ 07601

THURSHOUS NU UZEUI

HLAUDER & FICKEON

EXAMINER I ≅0 ← Patrick Twomey, Ph.D.

ART UNIT

PAPER NUMBER

1804

6

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application.

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Any inquiry concerning this communication should be directed to Examiner Patrick Twomey, Ph.D., Art Unit 1804, whose telephone number is (703) 305-7022.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Patrick Twomey, Ph.D. October 8, 1996

DEBORAH CAQUEL PATENT EXAMINEN GROUP 1600

DOCKETED CPI

Deheren Cand